Updates are available Correction dated 2025-11-01

Article History

Accepted: 23 July 2025

First Online: 26 September 2025

Change Date: 1 November 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40257-025-00989-x

Declarations

:

: LEO Pharma A/S funded the DELTA 1 and DELTA 2 trials and the preparation of this summary review article.

: Please see the original article for full author disclosures for Robert Bissonnette and Sibylle Schliemann. Fatima Albreiki has no conflicts of interest that are directly relevant to the content of this article. Benjamin D. Ehst has received fees/honoraria/royalties as an advisory board member, contributor, and/or consultant for AbbVie, Arcutis Biotherapeutics, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Incyte, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Proivant, UCB, and Up-To-Date; received speaking fees from AbbVie, Dermavant Sciences, Eli Lilly, Incyte, LEO Pharma, Navigator Medicines, Novartis, National Psoriasis Foundation, Ortho Dermatologics, Regeneron, and Sanofi-Genzyme; received institutional funding as an investigator for AbbVie, Aclaris Therapeutics, Allakos, Almirall, Alumis, Amgen, Apogee, Arcutis Biotherapeutics, BMS, Celgene, Celldex, Concert Pharmaceuticals, Dermavant Sciences, DermBiont, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen Biotech, Kymab, LEO Pharma, Novan, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, Takeda, UCB, and Ventyx Biosciences. Anwar Al Hammadi, Bin Yang, and Jianzhong Zhang have no conflicts of interest that are directly relevant to the content of this article. Christopher G. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber, and Palvella; a consultant for AbbVie, Almirall, Amgen, Apogee, Arcutis, Botanix, Connect BioPharma, Dermavant, Eli Lilly, EPI Health/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Teladoc, and UCB; and a speaker for and received honoraria from Allergan, Almirall, LEO Pharma, and UCB.

: This article is based on previously conducted trials and does not contain any new studies with human participants or animals performed by any of the authors. Please see the referenced article for the ethics approvals relating to the original trials.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Concept and content review at each draft stage of this Summary of Research Article was undertaken by all authors. The final submission was approved by all authors. The authors received no honoraria related to the development of this Summary of Research Article.